Workflow
Neumora Therapeutics, Inc. (NMRA) Discusses NMRA-215 Preclinical Results and Portfolio Updates, Including Obesity and Alzheimer's Disease Programs Transcript

PresentationLadies and gentlemen, thank you for standing by. [Operator Instructions] Please be advised that today's conference is being recorded. I would now like to turn the conference over to Helen Rubinstein, Vice President Investor Relations and Communications of Neumora. Please go ahead.Helen RubinsteinHead of Investor Relations Good morning, everyone, and thank you for joining us for today's event. Before we begin, I'd like to point out that this presentation contains forward-looking statements, which ...